Axsome Therapeutics, Inc. (NASDAQ: AXSM) has released the topline results from the crescendo (Characterizing Patient Perspectives on Unmet Needs in Narcolepsy) survey, shedding light on the challenges faced by patients with narcolepsy type 1 (NT1) despite receiving treatment. The survey, conducted in partnership with Narcolepsy Network, included 203 adult patients diagnosed with NT1, with a collective experience of over 2600 years with the sleep disorder.
The survey revealed that 77% of NT1 patients continue to experience cataplexy attacks despite being treated. Additionally, 64% of patients continue to suffer from excessive daytime sleepiness, as assessed by the Epworth Sleepiness Scale (ESS), and 74% exhibit cognitive impairment, as assessed by the British Columbia Cognitive Complaints Inventory (BC-CCI). Furthermore, depression and anxiety were reported by 45% and 57% of NT1 patients, respectively.
The majority of surveyed patients were undergoing treatment with wake-promoting agents (53%), oxybates (47%), and stimulants (42%). Despite these treatments, a significant portion of patients still reported persistent symptoms. For instance, 65% of those experiencing cataplexy reported that it burdens their professional life, while 60% reported a burden on their social life and 50% on their day-to-day life.
The survey was conducted between October and December 2023 and the detailed results are expected to be presented at upcoming scientific meetings. Dr. Karl Doghramji, a prominent figure in the field, emphasized the debilitating nature of narcolepsy and the importance of raising awareness about its impact on patients' lives.
Narcolepsy, characterized by symptoms such as excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, sleep paralysis, and disrupted nocturnal sleep, significantly interferes with cognitive, psychological, and social functioning. It is associated with a 1.5-fold higher mortality rate and poses risks for work* and driving-related accidents.
The findings from the crescendo survey underscore the unmet needs and significant burden faced by NT1 patients, despite the availability of treatments. Axsome Therapeutics, Inc. is dedicated to developing novel therapies for central nervous system conditions to address such unmet needs and improve the lives of patients. As a result of these announcements, the company's shares have moved -5.1% on the market, and are now trading at a price of $76.53. If you want to know more, read the company's complete 8-K report here.
